(Q37595494)

21 August 2017

1 reference

title

Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis (English)

1 reference

21 August 2017

1

Sohita Dhillon

1 reference

PubMed ID

19747014

21 August 2017

language of work or name

1 reference

1 October 2009

1 reference

21 August 2017

1 reference

21 August 2017

69

1 reference

21 August 2017

2005-2024

1 reference

21 August 2017

14

1 reference

https://scigraph.springernature.com/pub.10.2165/10489160-000000000-00000

21 August 2017

0 references

cites work

Endothelin-1 potentiates human smooth muscle cell growth to PDGF: effects of ETA and ETB receptor blockade

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F10489160-000000000-00000

Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects.

21 January 2018

1 reference

12 December 2020

EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).

1 reference

12 December 2020

Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: results from the European Postmarketing Surveillance program

1 reference

12 December 2020

Results of European post-marketing surveillance of bosentan in pulmonary hypertension.

1 reference

12 December 2020

Effects of the endothelin receptor antagonist bosentan on hemodynamics, symptoms and functional capacity in Japanese patients with severe pulmonary hypertension

1 reference

12 December 2020

Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil

1 reference

12 December 2020

Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatin

1 reference

12 December 2020

Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers

1 reference

12 December 2020

Treatment of complications associated with systemic sclerosis

1 reference

12 December 2020

Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol.

1 reference

12 December 2020

Improvement of vascular endothelial function using the oral endothelin receptor antagonist bosentan in patients with systemic sclerosis

1 reference

12 December 2020

Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs

1 reference

12 December 2020

Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

1 reference

12 December 2020

Increased plasma endothelin-1 immunoreactive levels in vasculitis: a clue to the use of endothelin-1 as a marker of vascular damage?

1 reference

12 December 2020

Pulmonary arterial hypertension in systemic sclerosis: the need for early detection and treatment

1 reference

12 December 2020

Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension.

1 reference

12 December 2020

Endothelin receptor antagonists: effect of serum albumin on potency and comparison of pharmacological characteristics

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole

1 reference

12 December 2020

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

1 reference

12 December 2020

Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients

1 reference

12 December 2020

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

1 reference

12 December 2020

Bosentan inhibits transient receptor potential channel expression in pulmonary vascular myocytes

1 reference

12 December 2020

Superiority of YM598 over atrasentan as a selective endothelin ETA receptor antagonist

1 reference

12 December 2020

Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management

1 reference

12 December 2020

Systemic sclerosis: hypothesis-driven treatment strategies

1 reference

12 December 2020

Clinical burden of digital vasculopathy in limited and diffuse cutaneous systemic sclerosis

1 reference

12 December 2020

Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis

1 reference

12 December 2020

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?

1 reference

12 December 2020

Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist

1 reference

12 December 2020

Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension

1 reference

12 December 2020

Bosentan for digital ulcers in patients with systemic sclerosis: a prospective 3-year followup study.

1 reference

12 December 2020

Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist

1 reference

12 December 2020

No effects of bosentan on microvasculature in patients with limited cutaneous systemic sclerosis

1 reference

12 December 2020

Bosentan regulates the expression of adhesion molecules on circulating T cells and serum soluble adhesion molecules in systemic sclerosis-associated pulmonary arterial hypertension

1 reference

12 December 2020

In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburide

1 reference

12 December 2020

Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist

1 reference

12 December 2020

1 reference

12 December 2020

Mutual pharmacokinetic interactions between steady-state bosentan and sildenafil

1 reference

12 December 2020

Endothelin and pulmonary arterial hypertension

1 reference

12 December 2020

Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases

1 reference

12 December 2020

The effect of bosentan on the pharmacokinetics of digoxin in healthy male subjects

1 reference

12 December 2020

Influence of severe renal dysfunction on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.

1 reference

12 December 2020

Effect of bosentan on plasma endothelin-1 concentration in patients with pulmonary arterial hypertension.

1 reference

12 December 2020

Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement?

1 reference

12 December 2020

Change in pharmacological effect of endothelin receptor antagonists in rats with pulmonary hypertension: role of ETB-receptor expression levels

1 reference

12 December 2020

Bosentan: a review of its use in pulmonary arterial hypertension and systemic sclerosis

1 reference

12 December 2020

Endothelin receptor antagonists in pulmonary arterial hypertension

1 reference

12 December 2020

Digital ulcers in patients with systemic sclerosis

1 reference

12 December 2020

Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A

1 reference

12 December 2020

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist

1 reference

12 December 2020

Digital ulcers: overt vascular disease in systemic sclerosis

1 reference

12 December 2020

The effect of bosentan on matrix metalloproteinase-9 levels in patients with systemic sclerosis-induced pulmonary hypertension

1 reference

12 December 2020

Macrovascular disease and atherosclerosis in SSc.

1 reference

12 December 2020

Bosentan increases serum IL-12 levels in systemic sclerosis patients with pulmonary arterial hypertension

1 reference

12 December 2020

Incidence and prevalence of systemic sclerosis: a systematic literature review

1 reference

12 December 2020

Overview of pathogenesis of systemic sclerosis

1 reference

12 December 2020

Role of N-terminal brain natriuretic peptide (N-TproBNP) in scleroderma-associated pulmonary arterial hypertension.

1 reference

12 December 2020

Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the endothelin-receptor antagonist bosentan in healthy human subjects.

1 reference

12 December 2020

Effect of the endothelin-receptor antagonist bosentan on the pharmacokinetics and pharmacodynamics of warfarin

1 reference

12 December 2020

Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects

1 reference

12 December 2020

The diagnosis and treatment of Raynaud's phenomenon: a practical approach.

1 reference

12 December 2020

10.2165/10489160-000000000-00000

Identifiers

DOI

1 reference

PubMed ID

19747014

Dimensions Publication ID

21 August 2017

0 references

1 reference

PubMed ID

19747014